HM
KZR

HealthCor Management’s Kezar Life Sciences KZR Stock Holding History

HealthCor Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-160,765
Closed -$13.8M – 44
2022
Q3 		$13.8M Buy
160,765
+39,777
+33% +$3.86M 1.73% 26
2022
Q2 		$10M Buy
+120,988
New +$10.7M 1.01% 32

Other funds holding KZR

APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

HealthCor Management's KZR Position: Q4 2022 in Review

HealthCor Management sold out of Kezar Life Sciences (KZR) in Q4 2022, closing a stake of 160,765 shares — an estimated $13.8M sold.

HealthCor Management first reported a position in KZR in Q2 2022 and held it in 2 quarters. The position peaked at $13.8M in Q3 2022. 121 funds tracked by Wall St. Rank hold KZR as of Q4 2022.

  • HealthCor Management reported no remaining Kezar Life Sciences position as of Q4 2022 after selling out during the quarter.
  • HealthCor Management sold 160,765 Kezar Life Sciences shares in Q4 2022, an estimated $13.8M.
  • HealthCor Management first reported a position in Kezar Life Sciences in Q2 2022 and held it in 2 quarters.
  • HealthCor Management's Kezar Life Sciences position peaked at $13.8M in Q3 2022.
  • 121 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2022.

Based on HealthCor Management's 13F filing for Q4 2022, filed 15 Feb 2023.